ACG Wealth Purchases Shares of 596 Zoetis Inc. (NYSE:ZTS)

view original post

ACG Wealth acquired a new stake in Zoetis Inc. (NYSE:ZTSGet Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 596 shares of the company’s stock, valued at approximately $102,000.

Other hedge funds also recently modified their holdings of the company. Horizon Investments LLC grew its holdings in shares of Zoetis by 5.5% in the 4th quarter. Horizon Investments LLC now owns 9,113 shares of the company’s stock valued at $2,220,000 after acquiring an additional 477 shares in the last quarter. Resources Management Corp CT ADV grew its holdings in shares of Zoetis by 18.7% in the 1st quarter. Resources Management Corp CT ADV now owns 3,112 shares of the company’s stock valued at $587,000 after acquiring an additional 491 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Zoetis by 4.5% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 151,858 shares of the company’s stock valued at $28,643,000 after acquiring an additional 6,593 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Zoetis by 6.3% in the 1st quarter. Revolve Wealth Partners LLC now owns 1,153 shares of the company’s stock valued at $217,000 after acquiring an additional 68 shares in the last quarter. Finally, Elk River Wealth Management LLC grew its holdings in Zoetis by 22.6% during the first quarter. Elk River Wealth Management LLC now owns 30,672 shares of the company’s stock worth $5,784,000 after purchasing an additional 5,651 shares during the period. Institutional investors own 91.05% of the company’s stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 4,334 shares of Zoetis stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the sale, the executive vice president now directly owns 23,687 shares in the company, valued at $4,145,225. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Roxanne Lagano sold 4,334 shares of Zoetis stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the sale, the executive vice president now directly owns 23,687 shares in the company, valued at $4,145,225. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Kristin C. Peck sold 9,689 shares of Zoetis stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the completion of the sale, the chief executive officer now owns 39,743 shares of the company’s stock, valued at $7,153,740. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,501 shares of company stock worth $2,949,073. Corporate insiders own 0.12% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Stifel Nicolaus reduced their price target on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a report on Friday, June 24th. Piper Sandler assumed coverage on Zoetis in a report on Monday, July 11th. They set an “overweight” rating and a $205.00 price target for the company. The Goldman Sachs Group reduced their price target on Zoetis from $208.00 to $202.00 and set a “buy” rating for the company in a report on Thursday, July 21st. Finally, William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Friday, August 5th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $224.00.

Zoetis Trading Down 1.2 %

Shares of NYSE:ZTS opened at $149.46 on Friday. Zoetis Inc. has a 12-month low of $148.96 and a 12-month high of $249.27. The stock has a market cap of $69.97 billion, a PE ratio of 33.89, a P/E/G ratio of 2.64 and a beta of 0.77. The business has a 50 day moving average of $167.61 and a 200-day moving average of $173.54. The company has a quick ratio of 1.46, a current ratio of 2.18 and a debt-to-equity ratio of 1.14.

Zoetis (NYSE:ZTSGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. The company’s revenue was up 7.8% on a year-over-year basis. As a group, equities research analysts forecast that Zoetis Inc. will post 5.01 earnings per share for the current year.

Zoetis Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts